Apellis Pharmaceuticals Inc (APLS)
27.73
+0.24
(+0.87%)
USD |
NASDAQ |
Nov 21, 16:00
27.73
0.00 (0.00%)
After-Hours: 20:00
Apellis Pharmaceuticals Revenue (Quarterly): 196.83M for Sept. 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 196.83M |
| June 30, 2024 | 199.68M |
| March 31, 2024 | 172.32M |
| December 31, 2023 | 146.38M |
| September 30, 2023 | 110.40M |
| June 30, 2023 | 94.97M |
| March 31, 2023 | 44.85M |
| December 31, 2022 | 22.66M |
| September 30, 2022 | 22.06M |
| Date | Value |
|---|---|
| June 30, 2022 | 16.32M |
| March 31, 2022 | 14.38M |
| December 31, 2021 | 60.29M |
| September 30, 2021 | 5.65M |
| June 30, 2021 | 0.623M |
| March 31, 2021 | |
| December 31, 2020 | 250.00M |
| September 30, 2020 | 0.646M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
0.623M
Minimum
Jun 2021
250.00M
Maximum
Dec 2020
84.88M
Average
52.57M
Median
Revenue (Quarterly) Benchmarks
| Biomarin Pharmaceutical Inc | 745.74M |
| Ionis Pharmaceuticals Inc | 133.81M |
| EyePoint Pharmaceuticals Inc | 10.52M |
| Cassava Sciences Inc | -- |
| Macrogenics Inc | 110.71M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -57.44M |
| Total Expenses (Quarterly) | 244.11M |
| EPS Diluted (Quarterly) | -0.46 |
| Enterprise Value | 3.475B |
| Gross Profit Margin (Quarterly) | 82.95% |
| Profit Margin (Quarterly) | -29.19% |
| Earnings Yield | -7.32% |
| Normalized Earnings Yield | -7.276 |